US20030229249A1 - Methods for producing nateglinide B-type crystals - Google Patents

Methods for producing nateglinide B-type crystals Download PDF

Info

Publication number
US20030229249A1
US20030229249A1 US10/421,888 US42188803A US2003229249A1 US 20030229249 A1 US20030229249 A1 US 20030229249A1 US 42188803 A US42188803 A US 42188803A US 2003229249 A1 US2003229249 A1 US 2003229249A1
Authority
US
United States
Prior art keywords
crystals
nateglinide
type crystals
type
crystal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US10/421,888
Inventor
Michito Sumikawa
Makoto Maruo
Kazuo Miyazaki
Shigehiro Nishina
Yukiko Matsuzawa
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ajinomoto Co Inc
Original Assignee
Ajinomoto Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ajinomoto Co Inc filed Critical Ajinomoto Co Inc
Assigned to AJINOMOTO CO., INC. reassignment AJINOMOTO CO., INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: MARUO, MAKOTO, MATSUZAWA, YUKIKO, MIYAZAKI, KAZUO, NISHINA, SHIGEHIRO, SUMIKAWA, MICHITO
Publication of US20030229249A1 publication Critical patent/US20030229249A1/en
Priority to US11/757,769 priority Critical patent/US7544834B2/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C227/00—Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C227/38—Separation; Purification; Stabilisation; Use of additives
    • C07C227/40—Separation; Purification
    • C07C227/42—Crystallisation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C231/00—Preparation of carboxylic acid amides
    • C07C231/22—Separation; Purification; Stabilisation; Use of additives
    • C07C231/24—Separation; Purification
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated

Definitions

  • the present invention relates to methods for producing nateglinide (its chemical name: N-(trans-4-isopropylcyclohexylcarbonyl)-D-phenylalanine) that is useful as a therapeutic agent for diabetes. More specifically, it relates to methods for producing nateglinide B-type crystals substantially free of H-type crystals.
  • nateglinide is useful as a therapeutic agent for diabetes because it effectively lowers blood glucose by oral administration (Japanese Patent Publication No. Hei 4-15221).
  • Japanese Patent Publication No. Hei 4-15221 Japanese Patent Publication No. Hei 4-15221.
  • the crystallization has to be carefully conducted under precisely controlled conditions in order to separate H-type crystals and difficulty of such crystallization procedure was problematic (see Japanese Patent No. 2,508,949).
  • one of crystal polymorphs of nateglinide has an advantage in that the B-type crystals can be easily prepared by conducting the crystallization under cooling.
  • the B-type crystals are transferred to the H-type crystals during the production stage.
  • H-type crystals were contaminated in the resulting B-type crystals.
  • a contamination of crystal polymorphs be as small as possible.
  • An object of the present invention is to provide methods for producing B-type crystals of nateglinide at an industrial scale without allowing other forms of the crystalline polymorphism to coexist.
  • the present invention provides a method for producing B-type crystals of nateglinide substantially free of H-type crystals, which comprises drying solvated wet crystals of nateglinide at a low temperature until no solvent remains and making a crystal conversion thereof.
  • the present invention provides a method for producing B-type crystals of nateglinide substantially free of H-type crystals, which comprises drying solvated materials containing nateglinide hydrates obtained by crystallizing out from a nateglinide-containing solution under cooling, at a temperature of 50° C. or lower until no solvent remains, and heating the resultant at a temperature of 60 to 110° C. to convert the crystal form of the resultant into B-type crystal.
  • Examples of the solvated wet crystals of nateglinide employed in the present invention include solvates with an alcohol such as methanol, ethanol and isopropyl alcohol, an acetate such as methyl acetate and ethyl acetate, or water.
  • the solvates with an alcohol or hydrate are usually used as the solvated wet crystals of nateglinide.
  • nateglinide is added to 60% ethanol aqueous solution so that the concentration of nateglinide becomes 5 wt %, dissolved at a temperature of around 30° C. and cooled down to 10° C. or lower to obtain the solvates.
  • the hydrates can be easily obtained by adding water to an alcohol solution, preferably ethanol solution, of nateglinide, cooling it to 10° C. or lower, thereby crystals are precipitated out, and separating the resulting crystals therefrom.
  • an alcohol solution preferably ethanol solution
  • nateglinide nateglinide
  • Solvated wet crystals obtained are dried until no solvent remains any longer.
  • the temperature employed may vary depending on the type and the amount of a solvent associated with the crystals, and may usually be 60° C. or lower, preferably 50° C. or lower. While no lower limit of the temperature is specified, a temperature of 20° C. or higher is usually employed in an economical point of view. Usually, it is preferable that the drying be conducted under the reduced pressure, and the drying can be completed in a short time of period when the pressure is as reduced as industrially possible.
  • the dried crystals obtained are converted into B-type crystals by heating at 60 to 110° C., preferably 70 to 110° C.
  • the crystal conversion is preferably conducted for 0.5 to 48 hours, more preferably 1 to 24 hours.
  • H-type crystals contaminated in the B-type crystals can be analyzed with DSC. It is preferable that no H-type crystals be detected by analyzing B-type crystals of nateglinide with the DSC.
  • the drying temperature at an early stage causes no substantial problem when wet B-type crystals of nateglinide are dried at a small scale in a laboratory since the solvent after the separation of the crystals remains only in a small amount and the drier can rapidly reach the maximum reduced pressure.
  • the B-type crystals free of H-type crystals can be produced according to methods of the present invention, even in a production at an industrial scale, for example, production of 5 Kg or more of the B-type crystals per one batch, in which the solvent remains in the crystals in a large amount after the separation from the liquid where the crystallization is conducted and the time period required for reaching the maximum reduced pressure is relatively long in the drying step.
  • the crystals were subjected to DSC, which revealed the presence of a peak specific to the B-type crystals (melting point: about 130° C.) without showing a peak specific to the H-type crystals (melting point: about 139° C.). Therefore, it is concluded that the resulting crystals are only B-type crystals which are substantially free of the H-type crystals.
  • B-type crystals of nateglinide can be produced at an industrial scale without allowing other crystal forms to be present, and a pharmaceutical formulation containing B-type crystals of nateglinide as a single nateglinide crystal can be provided at a low cost.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

A method for producing B-type crystals of nateglinide substantially free of H-type crystals is provided, which comprises drying solvated wet crystals of nateglinide at a low temperature until no solvent remains and making a crystal conversion thereof. According to this method, B-type crystals of nateglinide can be produced at an industrial scale without allowing other forms of the crystalline polymorphism to coexist.

Description

    BACKGROUND OF THE INVENTION
  • The present invention relates to methods for producing nateglinide (its chemical name: N-(trans-4-isopropylcyclohexylcarbonyl)-D-phenylalanine) that is useful as a therapeutic agent for diabetes. More specifically, it relates to methods for producing nateglinide B-type crystals substantially free of H-type crystals. [0001]
  • It is known that nateglinide is useful as a therapeutic agent for diabetes because it effectively lowers blood glucose by oral administration (Japanese Patent Publication No. Hei 4-15221). In this connection, the crystallization has to be carefully conducted under precisely controlled conditions in order to separate H-type crystals and difficulty of such crystallization procedure was problematic (see Japanese Patent No. 2,508,949). [0002]
  • On the other hand, one of crystal polymorphs of nateglinide, B-type crystals, has an advantage in that the B-type crystals can be easily prepared by conducting the crystallization under cooling. However, there is a possibility in that the B-type crystals are transferred to the H-type crystals during the production stage. In fact, when nateglinide was prepared in industrial scale, it was found that H-type crystals were contaminated in the resulting B-type crystals. Regarding nateglinide to be used as a medicine, it is preferable that a contamination of crystal polymorphs be as small as possible. Since the single crystalline form is the best desired, a method for producing B-type crystals of nateglinide by which a pharmaceutical formulation containing the B-type crystal exclusively without allowing other forms of the crystalline polymorphs to coexist has been desired to be developed. [0003]
    • DISCLOSURE OF THE INVENTION
  • An object of the present invention is to provide methods for producing B-type crystals of nateglinide at an industrial scale without allowing other forms of the crystalline polymorphism to coexist. [0004]
  • In the course of the study for the purpose of an efficient utilization of B-type crystals of nateglinide, the present inventors have found that a single crystal form of nateglinide can be produced at an industrial scale by selecting the conditions of the manufacturing process of nateglinide, and thus the present invention has been completed on the basis of this finding. [0005]
  • That is, the present invention provides a method for producing B-type crystals of nateglinide substantially free of H-type crystals, which comprises drying solvated wet crystals of nateglinide at a low temperature until no solvent remains and making a crystal conversion thereof. [0006]
  • Preferably, the present invention provides a method for producing B-type crystals of nateglinide substantially free of H-type crystals, which comprises drying solvated materials containing nateglinide hydrates obtained by crystallizing out from a nateglinide-containing solution under cooling, at a temperature of 50° C. or lower until no solvent remains, and heating the resultant at a temperature of 60 to 110° C. to convert the crystal form of the resultant into B-type crystal. [0007]
    • BEST MODE FOR CARRYING OUT THE INVENTION
  • Examples of the solvated wet crystals of nateglinide employed in the present invention include solvates with an alcohol such as methanol, ethanol and isopropyl alcohol, an acetate such as methyl acetate and ethyl acetate, or water. The solvates with an alcohol or hydrate are usually used as the solvated wet crystals of nateglinide. In cases of the solvates with ethanol, for example, nateglinide is added to 60% ethanol aqueous solution so that the concentration of nateglinide becomes 5 wt %, dissolved at a temperature of around 30° C. and cooled down to 10° C. or lower to obtain the solvates. [0008]
  • Among these, it is preferable that the hydrates can be easily obtained by adding water to an alcohol solution, preferably ethanol solution, of nateglinide, cooling it to 10° C. or lower, thereby crystals are precipitated out, and separating the resulting crystals therefrom. [0009]
  • Solvated wet crystals obtained are dried until no solvent remains any longer. In this step, the temperature employed may vary depending on the type and the amount of a solvent associated with the crystals, and may usually be 60° C. or lower, preferably 50° C. or lower. While no lower limit of the temperature is specified, a temperature of 20° C. or higher is usually employed in an economical point of view. Usually, it is preferable that the drying be conducted under the reduced pressure, and the drying can be completed in a short time of period when the pressure is as reduced as industrially possible. [0010]
  • While the drying at a low temperature can be continued until substantially no solvent remains any longer, no complete absence of the solvent is required, and the solvent may be present in an amount of about 5% by weight since it will be lost also upon the crystal conversion. [0011]
  • The dried crystals obtained are converted into B-type crystals by heating at 60 to 110° C., preferably 70 to 110° C. Usually, the crystal conversion is preferably conducted for 0.5 to 48 hours, more preferably 1 to 24 hours. [0012]
  • H-type crystals contaminated in the B-type crystals can be analyzed with DSC. It is preferable that no H-type crystals be detected by analyzing B-type crystals of nateglinide with the DSC. [0013]
  • Rising of the drying temperature at an early stage causes no substantial problem when wet B-type crystals of nateglinide are dried at a small scale in a laboratory since the solvent after the separation of the crystals remains only in a small amount and the drier can rapidly reach the maximum reduced pressure. However, the B-type crystals free of H-type crystals can be produced according to methods of the present invention, even in a production at an industrial scale, for example, production of 5 Kg or more of the B-type crystals per one batch, in which the solvent remains in the crystals in a large amount after the separation from the liquid where the crystallization is conducted and the time period required for reaching the maximum reduced pressure is relatively long in the drying step. [0014]
  • The present invention is further demonstrated with reference to the following examples, which are not intended to restrict the invention.[0015]
    • EXAMPLE 1
  • 24.5 kg of H-type crystals of nateglinide were added to 360 L of ethanol and dissolved by stirring at room temperature. 240 L of water was added thereto and cooled to 5° C. after ensuring the dissolution, and then the solution was subjected to aging at 5° C. for 1 hour. The thus-precipitated crystals were separated to obtain 43.0 kg of wet crystals. The crystals were dried on a rack drier at 45° C. for 24 hours (moisture content about 1 wt %) and further at 90° C. for 12 hours to make the crystal conversion to obtain 13.3 kg of dried crystals. The crystals were subjected to DSC, which revealed the presence of a peak specific to the B-type crystals (melting point: about 130° C.) without showing a peak specific to the H-type crystals (melting point: about 139° C.). Therefore, it is concluded that the resulting crystals are only B-type crystals which are substantially free of the H-type crystals. [0016]
    • COMPARATIVE 1
  • 37.0 kg of H-type crystals of nateglinide were added to 540 L of ethanol and dissolved by stirring at room temperature. 360 L of water was added thereto and cooled to 5° C. after ensuring the dissolution, and then the solution was subjected to aging at 5° C. for 1 hour. The thus-precipitated crystals were separated to obtain 46.7 kg of wet crystals. The crystals were dried with a conical drier at 30° C. for 3 hours (moisture content about 10 wt %) and further at 90° C. for 12 hours to make the crystal conversion to obtain 25.9 kg of dried crystals. The crystals were subjected to DSC, which showed peaks specific to the H-type crystals in addition to the B-type crystals. [0017]
    • COMPARATIVE 2
  • 37.0 kg of H-type crystals of nateglinide were added to 540 L of ethanol and dissolved by stirring at room temperature. 360 L of water was added thereto and cooled to 5° C. after ensuring the dissolution, and then the solution was subjected to aging at 5° C. for 1 hour. The thus-precipitated crystals were separated to obtain 44.5 kg of wet crystals. The crystals were dried with a conical drier at 30° C. for 3 hours (moisture content about 10 wt %) and further at 90° C. for 15 hours to make the crystal conversion to obtain 26.6 kg of dried B-type crystals. The crystals were subjected to DSC, which showed peaks specific to the H-type crystals in addition to the B-type crystals. [0018]
  • By employing the conditions according to the invention, B-type crystals of nateglinide can be produced at an industrial scale without allowing other crystal forms to be present, and a pharmaceutical formulation containing B-type crystals of nateglinide as a single nateglinide crystal can be provided at a low cost. [0019]

Claims (9)

What is claimed is:
1. A method for producing B-type crystals of nateglinide substantially free of H-type crystals, which comprises drying solvated wet crystals of nateglinide at a low temperature until no solvent remains and making a crystal conversion thereof.
2. The method of claim 1, wherein the resulting B-type crystals of nateglinide are crystals wherein H-type crystals are not detected with DSC.
3. The method of claim 1, wherein the drying is conducted at a temperature of 50° C. or lower.
4. The method of claim 1, wherein the drying is conducted until substantially no solvent remains any longer.
5. The method of claim 1, wherein the solvated wet crystals are hydrates.
6. The method of claim 1, wherein the crystal conversion is conducted by heating the solvated wet crystals at 60 to 110° C.
7. The method of claim 1, wherein said both steps for drying said solvated wet crystal of nateglinide at a low temperature and for the crystal conversion are conducted at an industrial scale.
8. A method for producing B-type crystals of nateglinide substantially free of H-type crystals, which comprises drying solvated materials containing nateglinide hydrates obtained by crystallizing out from a nateglinide-containing solution under cooling, at a temperature of 50° C. or lower until no solvent remains, and heating the resultant at a temperature of 60 to 110° C. to convert the crystal form of the resultant into B-type crystal.
9. The method of claim 8, wherein the resulting B-type crystals of nateglinide are crystals wherein H-type crystals are not detected with DSC.
US10/421,888 2000-10-24 2003-04-24 Methods for producing nateglinide B-type crystals Abandoned US20030229249A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US11/757,769 US7544834B2 (en) 2000-10-24 2007-06-04 Methods for producing nateglinide B-type crystals

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2000-324375 2000-10-24
JP2000324375 2000-10-24
PCT/JP2001/009293 WO2002034713A1 (en) 2000-10-24 2001-10-23 Process for producing b-form nateglinide crystal

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2001/009293 Continuation WO2002034713A1 (en) 2000-10-24 2001-10-23 Process for producing b-form nateglinide crystal

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US11/757,769 Continuation US7544834B2 (en) 2000-10-24 2007-06-04 Methods for producing nateglinide B-type crystals

Publications (1)

Publication Number Publication Date
US20030229249A1 true US20030229249A1 (en) 2003-12-11

Family

ID=18801920

Family Applications (2)

Application Number Title Priority Date Filing Date
US10/421,888 Abandoned US20030229249A1 (en) 2000-10-24 2003-04-24 Methods for producing nateglinide B-type crystals
US11/757,769 Expired - Fee Related US7544834B2 (en) 2000-10-24 2007-06-04 Methods for producing nateglinide B-type crystals

Family Applications After (1)

Application Number Title Priority Date Filing Date
US11/757,769 Expired - Fee Related US7544834B2 (en) 2000-10-24 2007-06-04 Methods for producing nateglinide B-type crystals

Country Status (18)

Country Link
US (2) US20030229249A1 (en)
EP (1) EP1334964B1 (en)
JP (1) JP4225057B2 (en)
KR (1) KR100810930B1 (en)
CN (1) CN100422143C (en)
AT (1) ATE370115T1 (en)
AU (1) AU2001296001A1 (en)
BR (1) BR0114846A (en)
CA (1) CA2426745C (en)
CY (1) CY1106839T1 (en)
DE (1) DE60130014T2 (en)
DK (1) DK1334964T3 (en)
ES (1) ES2288997T3 (en)
MX (1) MXPA03003575A (en)
PT (1) PT1334964E (en)
RU (1) RU2275354C2 (en)
TW (1) TWI293290B (en)
WO (1) WO2002034713A1 (en)

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030073729A1 (en) * 2000-03-17 2003-04-17 Ajinomoto Co. Inc Medicaments for diabetic complication and neuropathy, and uses thereof
US20040014815A1 (en) * 2000-10-24 2004-01-22 Ajinomoto Co. Inc. Nateglinide-containing preparation
US20040024219A1 (en) * 2000-10-18 2004-02-05 Ajinomoto Co. Inc Methods for producing acylphenylalanine
US20040030182A1 (en) * 2000-10-18 2004-02-12 Ajinomoto Co. Inc. Methods for producing nateglinide crystals
US20040029968A1 (en) * 2000-10-24 2004-02-12 Ajinomoto Co. Inc Nateglinide-containing hydrophilic pharmaceutical preparation
WO2005110395A1 (en) * 2004-05-19 2005-11-24 University Of South Carolina System and device for magnetic drug targeting with magnetic drug carrier particles
WO2005113485A2 (en) * 2004-05-20 2005-12-01 Dr. Reddy's Laboratories Ltd. Stable nateglinide form b compositions
WO2007135533A1 (en) * 2006-05-23 2007-11-29 Aurobindo Pharma Limited Process for preparing nateglinide b-type crystals
US20070275999A1 (en) * 2005-01-31 2007-11-29 Ajinomoto Co., Inc. Pharmaceutical compositions containing a hypoglycemic agent(s) for improving or treating impaired glucose tolerance, borderline diabetes, insulin resistance or hyperinsulinemia
US7411089B2 (en) 2002-04-15 2008-08-12 Ajinomoto Co., Inc. Nateglinide crystals
US20080319075A1 (en) * 2002-07-18 2008-12-25 Ronit Yahalomi Polymorphic forms of nateglinide
WO2011157986A1 (en) 2010-06-14 2011-12-22 Cipla Limited A process for the preparation of nateglinide

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003236243A1 (en) * 2002-04-15 2003-10-27 Ajinomoto Co., Inc. Novel nateglinide crystal
US6861553B2 (en) 2002-07-03 2005-03-01 Teva Pharmaceuticals Industries Ltd. Process for preparing nateglinide and intermediates thereof
AU2003253971A1 (en) * 2002-07-18 2004-02-09 Teva Pharmaceutical Industries Ltd. Polymorphic forms of nateglinide
US7534913B2 (en) 2002-07-18 2009-05-19 Teva Pharmaceutica Industries Ltd. Crystalline form of nateglinide
US7358390B2 (en) 2002-07-18 2008-04-15 Teva Pharmaceutical Industries Ltd. Polymorphic forms of nateglinide
US7148376B2 (en) 2002-07-18 2006-12-12 Teva Pharmaceutical Industries Ltd. Polymorphic forms of nateglinide
ATE349418T1 (en) * 2003-11-26 2007-01-15 A M S A Anonima Materie Sint E METHOD FOR PRODUCING B-FORM NATEGLINIDINE
EP1656339A1 (en) * 2004-05-07 2006-05-17 Teva Pharmaceutical Industries Ltd Polymorphic forms of nateglinide
US7425648B2 (en) 2005-01-03 2008-09-16 A.M.S.A. Anonima Materie Sintetiche E. Affini S.P.A. Process for the preparation of nateglinide, preferably in B-form
KR100837843B1 (en) * 2006-12-26 2008-06-13 씨제이제일제당 (주) Crystalline form of nateglinide, process for the preparation thereof, and pharmaceutical composition comprising the same
WO2014037832A2 (en) 2012-09-06 2014-03-13 Mahesh Kandula Compositions and methods for the treatment of epilepsy and neurological diseases
WO2013167990A1 (en) 2012-05-07 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of depression
CN104603096A (en) 2012-05-07 2015-05-06 塞利克斯比奥私人有限公司 Compositions and methods for treatment of neuromuscular disorders and neurodegenerative disorders
US9738631B2 (en) 2012-05-07 2017-08-22 Cellix Bio Private Limited Compositions and methods for the treatment of neurological disorders
AU2013257708A1 (en) * 2012-05-08 2014-12-04 Cellixbio Private Limited Compositions and methods for the treatment of diabetes
WO2013167992A1 (en) 2012-05-08 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of inflammatory disorders
WO2013168023A1 (en) 2012-05-08 2013-11-14 Mahesh Kandula Compositions and methods for treatment of parkinson's disease
US9522884B2 (en) 2012-05-08 2016-12-20 Cellix Bio Private Limited Compositions and methods for the treatment of metabolic disorders
WO2013167993A1 (en) 2012-05-08 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of neurological degenerative disorders
WO2013168025A1 (en) 2012-05-08 2013-11-14 Mahesh Kandula Compositions and methods for treatment of blood clotting disorders
WO2013168002A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of neurological conditions
US9242939B2 (en) 2012-05-10 2016-01-26 Cellix Bio Private Limited Compositions and methods for the treatment of respiratory disorders
US9273061B2 (en) 2012-05-10 2016-03-01 Cellix Bio Private Limited Compositions and methods for the treatment of chronic pain
WO2013167999A2 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of neurologic diseases
US9339484B2 (en) 2012-05-10 2016-05-17 Cellix Bio Private Limited Compositions and methods for the treatment of restless leg syndrome and fibromyalgia
WO2013168014A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of familial amyloid polyneuropathy
US9573927B2 (en) 2012-05-10 2017-02-21 Cellix Bio Private Limited Compositions and methods for the treatment of severe pain
WO2013168016A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of metabolic syndrome
WO2013168004A2 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of fibromyalgia pain
US9321775B2 (en) 2012-05-10 2016-04-26 Cellix Bio Private Limited Compositions and methods for the treatment of moderate to severe pain
WO2013167997A2 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of metabolic syndrome
US9499526B2 (en) 2012-05-10 2016-11-22 Cellix Bio Private Limited Compositions and methods for the treatment of neurologic diseases
US9394288B2 (en) 2012-05-10 2016-07-19 Cellix Bio Private Limited Compositions and methods for the treatment of asthma and allergy
US9227974B2 (en) 2012-05-23 2016-01-05 Cellex Bio Private Limited Compositions and methods for the treatment of respiratory disorders
WO2013175376A2 (en) 2012-05-23 2013-11-28 Mahesh Kandula Compositions and methods for the treatment of local pain
WO2013175344A2 (en) 2012-05-23 2013-11-28 Mahesh Kandula Compositions and methods for the treatment of periodontitis and rheumatoid arthritis
US9498461B2 (en) 2012-05-23 2016-11-22 Cellix Bio Private Limited Compositions and methods for the treatment of inflammatory bowel disease
JP2015518854A (en) 2012-05-23 2015-07-06 セリックスビオ プライヴェート リミテッド Compositions and methods for the treatment of multiple sclerosis
CN104583182A (en) 2012-05-23 2015-04-29 塞利克斯比奥私人有限公司 Compositions and methods for treatment of mucositis
US9108942B1 (en) 2014-11-05 2015-08-18 Mahesh Kandula Compositions and methods for the treatment of moderate to severe pain
US9187427B2 (en) 2012-08-03 2015-11-17 Cellix Bio Private Limited N-substituted nicotinamide compounds and compositions for the treatment migraine and neurologic diseases
US9624168B2 (en) 2012-09-06 2017-04-18 Cellix Bio Private Limited Compositions and methods for the treatment inflammation and lipid disorders
WO2014037834A2 (en) 2012-09-08 2014-03-13 Mahesh Kandula Compositions and methods for the treatment of inflammation and lipid disorders
US9333187B1 (en) 2013-05-15 2016-05-10 Cellix Bio Private Limited Compositions and methods for the treatment of inflammatory bowel disease
WO2014195961A1 (en) 2013-06-04 2014-12-11 Mahesh Kandula Compositions and methods for the treatment of diabetes and pre-diabetes
US9096537B1 (en) 2014-12-31 2015-08-04 Mahesh Kandula Compositions and methods for the treatment of mucositis
WO2016046835A1 (en) 2014-09-26 2016-03-31 Cellix Bio Private Limited Compositions and methods for the treatment of epilepsy and neurological disorders
CA2967908C (en) 2014-09-29 2020-11-17 Mahesh Kandula Compositions and methods for the treatment of multiple sclerosis
AU2014414316B2 (en) 2014-10-27 2020-04-09 Cellix Bio Private Limited Three component salts of fumaric acid monomethyl ester with piperazine or ethylene diamine for the treatment of multiple sclerosis
US10208014B2 (en) 2014-11-05 2019-02-19 Cellix Bio Private Limited Compositions and methods for the treatment of neurological disorders
US9175008B1 (en) 2014-11-05 2015-11-03 Cellix Bio Private Limited Prodrugs of anti-platelet agents
US9284287B1 (en) 2014-11-05 2016-03-15 Cellix Bio Private Limited Compositions and methods for the suppression of carbonic anhydrase activity
US9150557B1 (en) 2014-11-05 2015-10-06 Cellix Bio Private Limited Compositions and methods for the treatment of hyperglycemia
US9321716B1 (en) 2014-11-05 2016-04-26 Cellix Bio Private Limited Compositions and methods for the treatment of metabolic syndrome
US9290486B1 (en) 2014-11-05 2016-03-22 Cellix Bio Private Limited Compositions and methods for the treatment of epilepsy
US9173877B1 (en) 2014-11-05 2015-11-03 Cellix Bio Private Limited Compositions and methods for the treatment of local pain
CN104402756B (en) * 2014-11-27 2016-08-31 天方药业有限公司 A kind of preparation method of high-purity Nateglinide
US9932294B2 (en) 2014-12-01 2018-04-03 Cellix Bio Private Limited Compositions and methods for the treatment of multiple sclerosis
US9206111B1 (en) 2014-12-17 2015-12-08 Cellix Bio Private Limited Compositions and methods for the treatment of neurological diseases
JP6679616B2 (en) 2015-01-06 2020-04-22 セリックス バイオ プライヴェート リミテッドＣｅｌｌｉｘ Ｂｉｏ Ｐｒｉｖａｔｅ Ｌｉｍｉｔｅｄ Compositions and methods for the treatment of inflammation and pain
CN109369443A (en) * 2018-11-05 2019-02-22 扬子江药业集团江苏海慈生物药业有限公司 A kind of preparation method of new Nateglinide H crystal form

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030021843A1 (en) * 1999-12-28 2003-01-30 Ajinomoto Co. Inc Antidiabetic preparation for oral administration
US20030073729A1 (en) * 2000-03-17 2003-04-17 Ajinomoto Co. Inc Medicaments for diabetic complication and neuropathy, and uses thereof
US20040014815A1 (en) * 2000-10-24 2004-01-22 Ajinomoto Co. Inc. Nateglinide-containing preparation
US20040024219A1 (en) * 2000-10-18 2004-02-05 Ajinomoto Co. Inc Methods for producing acylphenylalanine
US20040030182A1 (en) * 2000-10-18 2004-02-12 Ajinomoto Co. Inc. Methods for producing nateglinide crystals
US6844008B2 (en) * 1996-11-15 2005-01-18 Ajinomoto Co., Inc. Tablet composition

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6354321A (en) * 1985-03-27 1988-03-08 Ajinomoto Co Inc Blood sugar lowering agent
DE10199058I2 (en) 1991-07-30 2006-04-27 Alcm Co Crystals of N- (trans-4-isopropylcyclohexylcarbonyl) -D-phenylalanine and process for their preparation
US5463116A (en) * 1991-07-30 1995-10-31 Ajinomoto Co., Inc. Crystals of N- (trans-4-isopropylcyclohexlycarbonyl)-D-phenylalanine and methods for preparing them
US6844006B1 (en) * 1999-07-09 2005-01-18 Pennfield Oil Company Process and apparatus for the preparation of chlortetracycline-containing animal feed compositions
US7411089B2 (en) 2002-04-15 2008-08-12 Ajinomoto Co., Inc. Nateglinide crystals

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6844008B2 (en) * 1996-11-15 2005-01-18 Ajinomoto Co., Inc. Tablet composition
US20030021843A1 (en) * 1999-12-28 2003-01-30 Ajinomoto Co. Inc Antidiabetic preparation for oral administration
US20030073729A1 (en) * 2000-03-17 2003-04-17 Ajinomoto Co. Inc Medicaments for diabetic complication and neuropathy, and uses thereof
US20040024219A1 (en) * 2000-10-18 2004-02-05 Ajinomoto Co. Inc Methods for producing acylphenylalanine
US20040030182A1 (en) * 2000-10-18 2004-02-12 Ajinomoto Co. Inc. Methods for producing nateglinide crystals
US20040014815A1 (en) * 2000-10-24 2004-01-22 Ajinomoto Co. Inc. Nateglinide-containing preparation

Cited By (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030073729A1 (en) * 2000-03-17 2003-04-17 Ajinomoto Co. Inc Medicaments for diabetic complication and neuropathy, and uses thereof
US7208622B2 (en) 2000-10-18 2007-04-24 Ajinomoto Co., Inc. Methods for producing nateglinide crystals
US20040024219A1 (en) * 2000-10-18 2004-02-05 Ajinomoto Co. Inc Methods for producing acylphenylalanine
US20040030182A1 (en) * 2000-10-18 2004-02-12 Ajinomoto Co. Inc. Methods for producing nateglinide crystals
US7659428B2 (en) 2000-10-18 2010-02-09 Ajinomoto Co., Inc. Methods for producing acylphenylalanine
US7030268B2 (en) 2000-10-18 2006-04-18 Ajinomoto Co., Inc. Methods for producing acylphenylalanine
US20060155143A1 (en) * 2000-10-18 2006-07-13 Ajinomoto Co. Inc Methods for producing acylphenylalanine
US20070167523A1 (en) * 2000-10-18 2007-07-19 Ajinomoto Co. Inc Methods for producing nateglinide crystals
US20090076301A1 (en) * 2000-10-18 2009-03-19 Ajinomoto Co. Inc Methods for producing nateglinide crystals
US7459582B2 (en) 2000-10-18 2008-12-02 Ajinomoto Co., Inc. Methods for producing nateglinide crystals
US20040029968A1 (en) * 2000-10-24 2004-02-12 Ajinomoto Co. Inc Nateglinide-containing hydrophilic pharmaceutical preparation
US7605180B2 (en) 2000-10-24 2009-10-20 Ajinomoto Co., Inc. Nateglinide-containing preparation
US20040014815A1 (en) * 2000-10-24 2004-01-22 Ajinomoto Co. Inc. Nateglinide-containing preparation
US20090203791A1 (en) * 2000-10-24 2009-08-13 Ajinomoto Co. Inc Nateglinide-containing preparation
US20080194867A1 (en) * 2002-04-15 2008-08-14 Ajinomoto Co., Inc. Nateglinide crystals
US7888531B2 (en) 2002-04-15 2011-02-15 Ajinomoto Co., Inc. Nateglinide crystals
US7977507B2 (en) 2002-04-15 2011-07-12 Ajinomoto Co., Inc. Nateglinide crystals
US20110092733A1 (en) * 2002-04-15 2011-04-21 Ajinomoto Co., Inc. Nateglinide crystals
US7411089B2 (en) 2002-04-15 2008-08-12 Ajinomoto Co., Inc. Nateglinide crystals
US20090253933A1 (en) * 2002-04-15 2009-10-08 Ajinomoto Co., Inc. Nateglinide crystals
US7586001B2 (en) 2002-04-15 2009-09-08 Ajinomoto Co., Inc. Nateglinide crystals
US20080319075A1 (en) * 2002-07-18 2008-12-25 Ronit Yahalomi Polymorphic forms of nateglinide
WO2005110395A1 (en) * 2004-05-19 2005-11-24 University Of South Carolina System and device for magnetic drug targeting with magnetic drug carrier particles
WO2005113485A2 (en) * 2004-05-20 2005-12-01 Dr. Reddy's Laboratories Ltd. Stable nateglinide form b compositions
WO2005113485A3 (en) * 2004-05-20 2009-04-30 Reddys Lab Ltd Dr Stable nateglinide form b compositions
US20070275999A1 (en) * 2005-01-31 2007-11-29 Ajinomoto Co., Inc. Pharmaceutical compositions containing a hypoglycemic agent(s) for improving or treating impaired glucose tolerance, borderline diabetes, insulin resistance or hyperinsulinemia
WO2007135533A1 (en) * 2006-05-23 2007-11-29 Aurobindo Pharma Limited Process for preparing nateglinide b-type crystals
WO2011157986A1 (en) 2010-06-14 2011-12-22 Cipla Limited A process for the preparation of nateglinide
US9150499B2 (en) 2010-06-14 2015-10-06 Cipla Limited Process for the preparation of nateglinide

Also Published As

Publication number Publication date
DE60130014D1 (en) 2007-09-27
WO2002034713A1 (en) 2002-05-02
EP1334964B1 (en) 2007-08-15
CN100422143C (en) 2008-10-01
CA2426745C (en) 2009-09-15
EP1334964A1 (en) 2003-08-13
TWI293290B (en) 2008-02-11
US7544834B2 (en) 2009-06-09
ES2288997T3 (en) 2008-02-01
US20070232829A1 (en) 2007-10-04
JPWO2002034713A1 (en) 2004-03-04
BR0114846A (en) 2004-02-25
JP4225057B2 (en) 2009-02-18
PT1334964E (en) 2007-09-20
DE60130014T2 (en) 2008-05-08
KR100810930B1 (en) 2008-03-10
ATE370115T1 (en) 2007-09-15
CN1483018A (en) 2004-03-17
CY1106839T1 (en) 2012-05-23
EP1334964A4 (en) 2005-09-28
MXPA03003575A (en) 2003-07-14
CA2426745A1 (en) 2003-04-23
KR20030059212A (en) 2003-07-07
RU2275354C2 (en) 2006-04-27
AU2001296001A1 (en) 2002-05-06
DK1334964T3 (en) 2007-09-24

Similar Documents

Publication Publication Date Title
US7544834B2 (en) Methods for producing nateglinide B-type crystals
US5057615A (en) Process for purifying tryptophan
JP2023524744A (en) Method for synthesizing lactic acid anhydride
EP0450684B1 (en) A process for the preparation of D-(-)-4-hydroxyphenylglycine and L-(+)-4-hydroxyphenylglycine, starting from D.L.-4-hydroxyphenylglycine
US20080275252A1 (en) Atipamezole Hydrochloride Crystallization Method
EP3474847B1 (en) Processes for the preparation of eluxadoline
US6316657B1 (en) Process for purification or recovery of sweetener
JP2007332050A (en) Manufacturing method of optically active n-tert-butylcarbamoyl-l-tert-leucine
WO2007135533A1 (en) Process for preparing nateglinide b-type crystals
CN106187799B (en) A method of preparing DL-lysine hydrochloride
US5874614A (en) Sodium (S)-2-(6-methoxy-2-naphthyl)propionate monohydrate
EP0481118A1 (en) A method for producing butyl 3'-(1H-tetrazol-5-yl) oxanilate
JPH08143585A (en) Purification of o,s-dimethyl-n-acetylphosphoramide thioate
CN108689914A (en) A method of chipal compounds are prepared using intermediate
US20080287685A1 (en) Detomidine Hydrochloride Crystallization Method
JP4397990B2 (en) Purification method of 3-alkylflavanonol derivatives
CN109627208A (en) A kind of purification process of Levamlodipine besylate
JPS62294637A (en) Purification of crude iburpofen
JP2011126825A (en) METHOD FOR PURIFYING OPTICALLY ACTIVE tert-LEUCINAMIDE
MXPA00002197A (en) Method of purifying and recovering sweetener
JPS63139181A (en) Crystallization of 2-(10,11-dihydro-10-oxodibenzo-(b, f)thiepin-2-yl)propionic acid
JPH0272138A (en) Separation of citric acid from isocitric acid
MXPA01002614A (en) METHOD FOR PRESSURELESS PRODUCTION OF&agr;,&agr;-DIMETHYLPHENYL ACETIC ACID FROM&agr;,&agr;-DIMETHYL BENZYL CYANIDE
JPH0231706B2 (en) TORANSUUHEKISAHIDOROTEREFUTARUSANNOSEIHO
JP2005068067A (en) Method for purifying 5,5-dimethylpyrroline-n-oxide

Legal Events

Date Code Title Description
AS Assignment

Owner name: AJINOMOTO CO., INC., JAPAN

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:SUMIKAWA, MICHITO;MARUO, MAKOTO;MIYAZAKI, KAZUO;AND OTHERS;REEL/FRAME:014412/0946

Effective date: 20030612

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION